A world leader in cGMP manufacturing of Viral-Based Gene Therapy products

About us

Where ideas become reality!

Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an unparalleled reputation in the gene therapy market.

Services

07.06.2023

NIB to finance FinVector's pharmaceutical gene therapy manufacturing

The Nordic Investment Bank (NIB) and Finnish FinVector Oy, a Ferring Ventures company, have signed a twelve-year EUR 45 million loan for the building of FinVector’s new viral-based gene therapy drug production unit in Kuopio, Finland.
11.04.2023

FinVector welcomes a New Managing Director to Kuopio

19.12.2022

A Major Milestone for FinVector Following U.S. FDA Approval for Bladder Cancer Gene Therapy

Ferring Pharmaceuticals, an affiliate company of Kuopio-based FinVector Oy, has announced the U.S. FDA approval of a new bladder cancer therapy developed by FinVector in Finland, and to be manufactured in Kuopio. The medicine will provide NMIBC (Non-Muscle Invasive Bladder Cancer) patients with an alternative option to invasive bladder removal surgery. The FDA approval constitutes a major milestone for the Finnish Life Science research community and industry, with a first-in-class gene therapy manufacturing capability.

Press Release in Finnish below.
<
5 / 2024
>
Wk Mon Tue Wed Thu Fri Sat Sun
18 29 30 1 2 3 4 5
19 6 7 8 9 10 11 12
20 13 14 15 16 17 18 19
21 20 21 22 23 24 25 26
22 27 28 29 30 31 1 2
More News & Events